- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06087068
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
October 13, 2023 updated by: liu jie, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Prospective, Single-arm Phase II Study of Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and has a good prognosis.According to the 2015 American thyroid association (ATA) guidelines, no gross extrathyroidal extension and the number of pathological lymph node micrometastases (<0.2cm) ≤5 were defined as the low recurrence risk group.
After total thyroidectomy and radioiodine treatment, the probability of disease-free status (irritant Tg<1ng/ml, no evidence of other disease recurrence) is about 78%-91%, and the probability of structural recurrence is about 1%-10%.
In recent years, due to the further understanding of PTC, surgeons tend to become more conservative in treatment, such as active observation or reducing the extent of surgery.
The indication for lobectomy has been extended to tumors <4cm without extrathyroidal extension and clinical lymph node metastasis.
For patients treated with lobectomy, current guidelines recommend that Thyroid Stimulating Hormone (TSH) be controlled at 0.5-2 mU/L, but evidence on the prognostic benefits of this TSH inhibition range is lacking.In recent years, a number of studies have suggested that if postoperative TSH in low-risk patients after lobectomy is acceptable within the reference range, it means that a considerable number of patients have a high probability of not receiving thyroxine replacement therapy after surgery, which can significantly improve their quality of life.A previous retrospective study from our institute showed no significant association between TSH levels after lobectomy and prognosis.The aim of this study was to evaluate the benefits and risks of postoperative TSH levels within the reference range (0.4-5 mU/L) in patients with low-risk papillary thyroid cancer who underwent lobectomy.In order to improve the effect of longer recurrence and death time of PTC, the investigators also performed postoperative thyroglobulin and its antibody for short-term treatment response evaluation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
140
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: jie liu
- Phone Number: +861087787180
- Email: liujie10-11@vip.163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Science
-
Contact:
- jie liu, MD
- Phone Number: 8610-87787180
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- (1) Age 18-70 years old, ECOG score 0-2;
- (2) Patients with the maximum diameter of unilateral thyroid nodules ≤4.0cm by ultrasound, papillary thyroid carcinoma diagnosed by preoperative cytology (Bethesda grade VI) or intraoperative freezing, and planned to undergo thyroid lobectomy;
- (3) No clinical lymph node metastasis (cN0);No extrathyroidal extension, and the number of pathological lymph node micrometastasis (<0.2cm) was ≤5.
- (4) no serious medical diseases and major organ dysfunction, such as blood routine, liver, kidney, heart, lung function; No previous history of other head and neck malignancies, no history of neck radiation, no history of deep neck surgery (skin mass excision except clinical);
- (5) Fully understand this study, have the ability to complete treatment, have follow-up conditions and voluntarily sign informed consent.
Exclusion Criteria:
- (1) History of malignancy in other sites (previous or simultaneous), excluding curable non-melanoma skin cancer and cervical carcinoma in situ;
- (2) The contralateral thyroid nodules were evaluated by preoperative ultrasound, and the patients with suspicious nodules who underwent fine-needle aspiration cytology and could not confirm the benign or malignant nodules (Bethesda grade I, III-V) were excluded.
- (3) Cervical lymph node metastasis was evaluated before surgery. Cytological aspiration and Tg eluent determination were performed on suspicious lymph nodes. If cytology was negative and Tg eluent was not higher than the normal range, it was not considered as exclusion criteria. The patients who were sent for intraoperative examination and showed metastasis were excluded.
- (4) cytological aspiration or intraoperative freezing suspected non-papillary thyroid carcinoma (follicular carcinoma, medullary carcinoma, poorly differentiated or undifferentiated carcinoma) or high-risk subtypes of papillary thyroid carcinoma (high cell type);
- (5) pregnant or lactating women;
- (6) A history of drug use or drug abuse within the past 1 year;
- (7) Participants who had participated in other clinical trials within 4 weeks before enrollment;
- (8) The patient is unable to accept the preservation of the contralateral gland or cannot cooperate with subsequent thyroid hormone replacement therapy.
- (9) The investigator assesses subjects who are unsuitable for the trial for other reasons, or who are not expected to complete the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: test group
The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
|
The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recurrence
Time Frame: 2 year
|
recurrence-free survival
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
thyroid function
Time Frame: 1 year; 2 year
|
biochemical incomplete (rising serum Tg)
|
1 year; 2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Estimated)
July 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
October 8, 2023
First Submitted That Met QC Criteria
October 13, 2023
First Posted (Actual)
October 17, 2023
Study Record Updates
Last Update Posted (Actual)
October 17, 2023
Last Update Submitted That Met QC Criteria
October 13, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Disease Attributes
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Adenocarcinoma, Papillary
- Recurrence
- Thyroid Diseases
- Thyroid Neoplasms
- Thyroid Cancer, Papillary
Other Study ID Numbers
- Cancer
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrence
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Chinese PLA General HospitalRecruitingHCC | Recurrence TumorChina
-
Paracelsus Medical UniversityHeinrich-Heine University, Duesseldorf; Poznan University of Medical Sciences; University Hospital of Ferrara and other collaboratorsCompletedToxicity | Local Neoplasm RecurrenceAustria
-
General Hospital GroeningeUniversitaire Ziekenhuizen KU Leuven; Jessa Hospital; University Hospital, Ghent and other collaboratorsNot yet recruiting
-
Dallas VA Medical CenterTerminatedSolid Tumors | Cancer RecurrenceUnited States
-
The University of Hong KongHealth and Medical Research FundNot yet recruitingCancer | Fear of Cancer Recurrence
-
German Centre for Assessment and Evaluation of...Not yet recruitingComplication | Continence | Potency | Biochemical RecurrenceGermany
-
The University of Hong KongNot yet recruitingCancer | Fear of Cancer Recurrence
-
RottapharmTerminatedHCV Recurrence After Liver Transplantation
-
The University of Hong KongHealth and Medical Research FundNot yet recruitingCancer | Fear of Cancer Recurrence | Psychooncology
Clinical Trials on Thyroxine
-
I.M. Sechenov First Moscow State Medical UniversityCompleted
-
Washington University School of MedicineMid-America TransplantCompleted
-
Tokyo Women's Medical UniversityTokyo Metropolitan Bokuto HospitalCompleted
-
Hawler Medical UniversityCompletedPregnancy Loss | Sub Clinical Hypothyroidism
-
Shandong Provincial HospitalUnknownEndocrine System Diseases | Hypothyroidism | Thyroid DiseasesChina
-
Shandong Provincial HospitalActive, not recruitingEndocrine System Diseases | Hypothyroidism | Thyroid DiseasesChina
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Meyer Children's HospitalUnknown
-
NHS Greater Glasgow and ClydeUniversity of Bern; Leiden University Medical Center; University College Cork; University...CompletedSubclinical HypothyroidismUnited Kingdom